MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

EQS-News: MorphoSys AG / Key word(s): Delisting MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market 12.07.2024 / 22:02 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, July 12, 2024 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced […]

Continue Reading

Clinical trial regulation should be simplified – Researchers call for ‘toolbox’ to bridge the gap between governance and reality –

London, 12 July 2024 – Governance and their practical implementation in early phase clinical trials require a new approach and simplification is the route to better safety according to an article in the latest issue of the British Journal of Clinical Pharmacology[1]. The editorial authors, Dr Ulrike Lorch, co-founder and Chief Medical Director at Richmond […]

Continue Reading

Clinion Wins The Technology Innovation Leadership Award by Frost & Sullivan

Leading the Way in Clinical Trial Innovation We are thrilled to announce that Clinion has been honored with The 2024 Technology Innovation Leadership Award by Frost & Sullivan. This award recognizes our trailblazing efforts in the North American clinical trial optimization industry. Clinion’s dedication to leveraging advanced technologies like GenAI and Automation has solidified our […]

Continue Reading

Pharma CCO Market Forecasts 5% CAGR by 2029, Highlighting Real-World Evidence Demand

The Global Pharma Contract Commercialization (CCO) Market is anticipated to grow at a CAGR of 5% by 2029. This growth is driven by several factors including increasing R&D costs, declining pharmaceutical sales, enhanced regulatory scrutiny, and the growing demand for market access, Real-World Evidence (RWE), Health Economics and Outcomes Research (HEOR), pricing and reimbursement, regulatory […]

Continue Reading